Lisinopril therapy for hemodialysis hypertension

Hemodynamic and endocrine responses

Rajiv Agarwal, Rebecca Lewis, Joyce L. Davis, Bruce Becker

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

To evaluate the antihypertensive effects of lisinopril, a renally excreted angiotensin-converting enzyme inhibitor, we assessed supervised administration of the drug after hemodialysis (HD) three times weekly. Blood pressure (BP) was assessed by interdialytic 44-hour ambulatory BP (ABP) monitoring, and endocrine responses were assessed by plasma renin activity (PRA) before and after dialysis. Lisinopril dose was titrated at biweekly intervals. If this was not effective after full titration (lisinopril to 40 mg three times weekly), ultrafiltration was added to reduce dry weight. The primary outcome variable was change In BP from the end of the run-in period to the end of the study. No change in mean ABP was noted during run-in. However, mean 44-hour ABP decreased from 149 ± 14 (SD)/84 ± 9 to 127 ± 16/73 ± 9 mm Hg, a decrease of 22/11 mm Hg (P < 0.001) at final evaluation. Of 11 patients who completed the trial, only 2 patients had systolic hypertension (≥135 mm Hg) and 1 patient had diastolic hypertension (≥85 mm Hg) at the final visit. Four patients were administered 10 mg of lisinopril; 5 patients, 20 mg; and 2 patients, 40 mg; only 1 of these patients required ultrafiltration therapy. There was a persistent antihypertensive effect over 44 hours. BP reduction was achieved without an increase in intradialytic symptomatic or asymptomatic hypotensive episodes. PRA increased in response to dialysis, as well as lisinopril. In conclusion, supervised lisinopril therapy is effective in controlling hypertension in chronic HD patients. This may be related to blockade of angiotensin II generation by kidneys despite the loss of excretory function.

Original languageEnglish
Pages (from-to)1245-1250
Number of pages6
JournalAmerican Journal of Kidney Diseases
Volume38
Issue number6
StatePublished - 2001

Fingerprint

Lisinopril
Renal Dialysis
Hemodynamics
Hypertension
Ultrafiltration
Therapeutics
Blood Pressure
Renin
Antihypertensive Agents
Dialysis
Ambulatory Blood Pressure Monitoring
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II
Kidney
Weights and Measures

Keywords

  • Ambulatory blood pressure monitoring (ABPM)
  • Anglotensin-converting enzyme (ACE) inhibitors
  • Antihypertensive therapy
  • Hemodialysis (HD)
  • Hypertension
  • Reninangiotensin system

ASJC Scopus subject areas

  • Nephrology

Cite this

Lisinopril therapy for hemodialysis hypertension : Hemodynamic and endocrine responses. / Agarwal, Rajiv; Lewis, Rebecca; Davis, Joyce L.; Becker, Bruce.

In: American Journal of Kidney Diseases, Vol. 38, No. 6, 2001, p. 1245-1250.

Research output: Contribution to journalArticle

Agarwal, Rajiv ; Lewis, Rebecca ; Davis, Joyce L. ; Becker, Bruce. / Lisinopril therapy for hemodialysis hypertension : Hemodynamic and endocrine responses. In: American Journal of Kidney Diseases. 2001 ; Vol. 38, No. 6. pp. 1245-1250.
@article{eb1a45b2cb254dfda3e580c19771fa3c,
title = "Lisinopril therapy for hemodialysis hypertension: Hemodynamic and endocrine responses",
abstract = "To evaluate the antihypertensive effects of lisinopril, a renally excreted angiotensin-converting enzyme inhibitor, we assessed supervised administration of the drug after hemodialysis (HD) three times weekly. Blood pressure (BP) was assessed by interdialytic 44-hour ambulatory BP (ABP) monitoring, and endocrine responses were assessed by plasma renin activity (PRA) before and after dialysis. Lisinopril dose was titrated at biweekly intervals. If this was not effective after full titration (lisinopril to 40 mg three times weekly), ultrafiltration was added to reduce dry weight. The primary outcome variable was change In BP from the end of the run-in period to the end of the study. No change in mean ABP was noted during run-in. However, mean 44-hour ABP decreased from 149 ± 14 (SD)/84 ± 9 to 127 ± 16/73 ± 9 mm Hg, a decrease of 22/11 mm Hg (P < 0.001) at final evaluation. Of 11 patients who completed the trial, only 2 patients had systolic hypertension (≥135 mm Hg) and 1 patient had diastolic hypertension (≥85 mm Hg) at the final visit. Four patients were administered 10 mg of lisinopril; 5 patients, 20 mg; and 2 patients, 40 mg; only 1 of these patients required ultrafiltration therapy. There was a persistent antihypertensive effect over 44 hours. BP reduction was achieved without an increase in intradialytic symptomatic or asymptomatic hypotensive episodes. PRA increased in response to dialysis, as well as lisinopril. In conclusion, supervised lisinopril therapy is effective in controlling hypertension in chronic HD patients. This may be related to blockade of angiotensin II generation by kidneys despite the loss of excretory function.",
keywords = "Ambulatory blood pressure monitoring (ABPM), Anglotensin-converting enzyme (ACE) inhibitors, Antihypertensive therapy, Hemodialysis (HD), Hypertension, Reninangiotensin system",
author = "Rajiv Agarwal and Rebecca Lewis and Davis, {Joyce L.} and Bruce Becker",
year = "2001",
language = "English",
volume = "38",
pages = "1245--1250",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Lisinopril therapy for hemodialysis hypertension

T2 - Hemodynamic and endocrine responses

AU - Agarwal, Rajiv

AU - Lewis, Rebecca

AU - Davis, Joyce L.

AU - Becker, Bruce

PY - 2001

Y1 - 2001

N2 - To evaluate the antihypertensive effects of lisinopril, a renally excreted angiotensin-converting enzyme inhibitor, we assessed supervised administration of the drug after hemodialysis (HD) three times weekly. Blood pressure (BP) was assessed by interdialytic 44-hour ambulatory BP (ABP) monitoring, and endocrine responses were assessed by plasma renin activity (PRA) before and after dialysis. Lisinopril dose was titrated at biweekly intervals. If this was not effective after full titration (lisinopril to 40 mg three times weekly), ultrafiltration was added to reduce dry weight. The primary outcome variable was change In BP from the end of the run-in period to the end of the study. No change in mean ABP was noted during run-in. However, mean 44-hour ABP decreased from 149 ± 14 (SD)/84 ± 9 to 127 ± 16/73 ± 9 mm Hg, a decrease of 22/11 mm Hg (P < 0.001) at final evaluation. Of 11 patients who completed the trial, only 2 patients had systolic hypertension (≥135 mm Hg) and 1 patient had diastolic hypertension (≥85 mm Hg) at the final visit. Four patients were administered 10 mg of lisinopril; 5 patients, 20 mg; and 2 patients, 40 mg; only 1 of these patients required ultrafiltration therapy. There was a persistent antihypertensive effect over 44 hours. BP reduction was achieved without an increase in intradialytic symptomatic or asymptomatic hypotensive episodes. PRA increased in response to dialysis, as well as lisinopril. In conclusion, supervised lisinopril therapy is effective in controlling hypertension in chronic HD patients. This may be related to blockade of angiotensin II generation by kidneys despite the loss of excretory function.

AB - To evaluate the antihypertensive effects of lisinopril, a renally excreted angiotensin-converting enzyme inhibitor, we assessed supervised administration of the drug after hemodialysis (HD) three times weekly. Blood pressure (BP) was assessed by interdialytic 44-hour ambulatory BP (ABP) monitoring, and endocrine responses were assessed by plasma renin activity (PRA) before and after dialysis. Lisinopril dose was titrated at biweekly intervals. If this was not effective after full titration (lisinopril to 40 mg three times weekly), ultrafiltration was added to reduce dry weight. The primary outcome variable was change In BP from the end of the run-in period to the end of the study. No change in mean ABP was noted during run-in. However, mean 44-hour ABP decreased from 149 ± 14 (SD)/84 ± 9 to 127 ± 16/73 ± 9 mm Hg, a decrease of 22/11 mm Hg (P < 0.001) at final evaluation. Of 11 patients who completed the trial, only 2 patients had systolic hypertension (≥135 mm Hg) and 1 patient had diastolic hypertension (≥85 mm Hg) at the final visit. Four patients were administered 10 mg of lisinopril; 5 patients, 20 mg; and 2 patients, 40 mg; only 1 of these patients required ultrafiltration therapy. There was a persistent antihypertensive effect over 44 hours. BP reduction was achieved without an increase in intradialytic symptomatic or asymptomatic hypotensive episodes. PRA increased in response to dialysis, as well as lisinopril. In conclusion, supervised lisinopril therapy is effective in controlling hypertension in chronic HD patients. This may be related to blockade of angiotensin II generation by kidneys despite the loss of excretory function.

KW - Ambulatory blood pressure monitoring (ABPM)

KW - Anglotensin-converting enzyme (ACE) inhibitors

KW - Antihypertensive therapy

KW - Hemodialysis (HD)

KW - Hypertension

KW - Reninangiotensin system

UR - http://www.scopus.com/inward/record.url?scp=0035722875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035722875&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 1245

EP - 1250

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 6

ER -